Wednesday, December 7, 2016

BRIEF-Voyager Therapeutics announces positive interim results from phase 1B trial of VY-AADC01

* Says VY-AADC01 dose-dependently improved measures of motor

function and enhanced response to levodopa at 6 and 12 months

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)